We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Quantify the Uptake and Distribution of Targeted Nanoparticles

By LabMedica International staff writers
Posted on 23 Dec 2009
Print article
Nanoparticles linked to targeting molecules are increasingly being cited as potential chemotherapeutic agents, and a recent publication has now quantified how such molecules are distributed to various organelles within a target cell.

Investigators at Purdue University (West Lafayette, IN, USA) worked with nanorods constructed of gold and a magnetic material and coated with trastuzumab, an anticancer drug used to used to treat breast cancer that has metastasized in women whose tumor cells produce an overabundance of human epidermal growth factor receptor 2 (HER2). The location of the nanorods in cultured breast cancer cells was determined by a combination of magnetic resonance spectrometry and microscopy. In some experiments, the drug was marked with a fluorescent molecule, and localization was quantified and diffusion times evaluated in different cell organelles by using fluorescence correlation spectroscopy (FCS).

Results published in the November 5, 2009, online edition of the journal ACS Nano revealed that, that in treated breast cancer cells the conjugated nanoparticles co-localized with the endosome and lysosome but not with the Golgi apparatus. The nanorods had similar intracellular localization characteristics as the fluorescently labeled drug. These findings not only lay the foundations for a quantitative understanding of the fate of nanoparticle-based targeting but also provide new insights into the rational design of nanoparticle delivery systems for effective treatment.

"Each nanoparticle acts like a deliverer of a mail package, or dose, of the drug directly to the appropriate location," said senior author Dr. Joseph Irudayaraj, professor of biological engineering at Purdue University. "We have demonstrated the ability to track these nanoparticles in different cellular compartments of live cells and show where they collect quantitatively. Our methods will allow us to calculate the quantities of a drug needed to treat a cancer cell because now we know how these nanoparticles are being distributed to different parts of the cell."

Related Links:
Purdue University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.